scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1019289712 |
P356 | DOI | 10.1186/S13561-014-0031-5 |
P932 | PMC publication ID | 4502065 |
P698 | PubMed publication ID | 26208931 |
P5875 | ResearchGate publication ID | 280387973 |
P2093 | author name string | Franz-Werner Dippel | |
Karlheinz Theobald | |||
David Gasche | |||
Andrea Lebioda | |||
Stefan Plantör | |||
P2860 | cites work | Individual patient-level and study-level meta-analysis for investigating modifiers of treatment effect. | Q52971736 |
Indirect Treatment Comparison/Network Meta-Analysis Study Questionnaire to Assess Relevance and Credibility to Inform Health Care Decision Making: An ISPOR-AMCP-NPC Good Practice Task Force Report | Q57542840 | ||
Network meta-analysis for indirect treatment comparisons | Q74720205 | ||
The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials | Q29619501 | ||
Meta-analysis of individual participant data: rationale, conduct, and reporting | Q33530020 | ||
Methods in health service research. An introduction to bayesian methods in health technology assessment | Q33716256 | ||
Bayesian methods for evidence synthesis in cost-effectiveness analysis | Q36381197 | ||
Direct versus indirect comparisons: a summary of the evidence | Q37133396 | ||
Use of indirect and mixed treatment comparisons for technology assessment | Q37259556 | ||
Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews | Q37433313 | ||
Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. | Q37888895 | ||
Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. | Q46894544 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 1 | |
P304 | page(s) | 31 | |
P577 | publication date | 2014-11-30 | |
P1433 | published in | Health Economics Review | Q27724295 |
P1476 | title | Relevance of indirect comparisons in the German early benefit assessment and in comparison to HTA processes in England, France and Scotland | |
P478 | volume | 4 |
Q31133870 | Comparison of post-authorisation measures from regulatory authorities with additional evidence requirements from the HTA body in Germany - are additional data requirements by the Federal Joint Committee justified? |
Q92062148 | Different interpretation of additional evidence for HTA by the commissioned HTA body and the commissioning decision maker in Germany: whenever IQWiG and Federal Joint Committee disagree |
Q38670350 | First-line therapy for non-transplant eligible patients with multiple myeloma: direct and adjusted indirect comparison of treatment regimens on the existing market in Germany |
Q89365659 | History and publication trends in the diffusion and early uptake of indirect comparison meta-analytic methods to study drugs: animated coauthorship networks over time |
Q49887834 | INDUSTRY'S EXPERIENCES WITH THE SCIENTIFIC ADVICE OFFERED BY THE FEDERAL JOINT COMMITTEE WITHIN THE EARLY BENEFIT ASSESSMENT OF PHARMACEUTICALS IN GERMANY. |
Q30240170 | Short-term and long-term efficacy of 7 targeted therapies for the treatment of advanced hepatocellular carcinoma: a network meta-analysis: Efficacy of 7 targeted therapies for AHCC. |